Ancora Biotech LLC

Ancora Biotech is focused on developing innovative biotherapeutics for B cell cancers, metabolic diseases, and chronic hepatitis B infections. Ancora has a pipeline of multi-specific antibodies in development, each targeting specific disease pathways. They have 3 lead products. TNB-486, which is a bispecific T cell engager designed to treat B cell cancers, TNB-738, which is an anti-CD38 enzyme inhibitor for treatment of inflammatory and metabolic disorders in the elderly, and Anti-HBVxCD3, which is a T cell engager treating chronic hepatitis B infections.

Jobs: